Global Gastric Cancer Market Assessment, By Type [Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others], By Stages [Stage I, Stage II, Stage III, Stage IV, Others], By Drug Class [PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others], By Diagnosis [Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Others], By Treatment [Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Others], By Route of Administration [Oral, Parenteral, Others], By Distribution Channel [Hospital Pharmacy, Online Pharmacy, Retail Pharmacy], By End-users [Hospitals, Homecare, Specialty Centers, Others], By Region, Opportunities and Forecast, 2017-2031F

Global gastric cancer market size was valued at USD 4.87 billion in 2023, which is expected to reach USD 12.83 billion in 2031, growing with a CAGR of 12.88% for the forecast period between 2024 and 2031F. The global gastric cancer market pertains to a comprehensive landscape involving the diagnosis, treatment, and research dedicated to gastric (stomach) cancer. Gastric cancer is a significant health concern worldwide, it poses a considerable medical, economic, and social burden. The market encompasses a broad spectrum of activities, including innovative therapies, diagnostic tools, supportive care, and ongoing clinical research to address the challenges associated with the disease. Advancements in the gastric cancer market primarily focus on early detection techniques, personalized treatment options, and improving patient outcomes.

Diagnostic procedures involve endoscopic examinations, imaging technologies, and molecular diagnostic tests to identify the disease at its initial stages, significantly impacting treatment success rates. The market's landscape is continually evolving due to the emergence of novel therapeutic approaches and the integration of cutting-edge technologies. Clinical trials and research initiatives are ongoing, exploring innovative treatment options, including immunotherapies, precision medicines, and combination therapies. Collaboration between pharmaceutical companies, research institutions, and healthcare providers is critical for advancing the understanding of gastric cancer and developing more effective and targeted therapies. Additionally, initiatives aimed at raising awareness, early detection, and providing education about risk factors and symptoms play a crucial role in the overall management of gastric cancer on a global scale. The evolving landscape of gastric cancer market holds promise for improved patient outcomes, emphasizing the importance of continued research, innovation, and collaboration in the field.

New Innovations

The global gastric cancer market has seen significant advancements in recent years, driven by innovative technologies and treatment approaches. One notable innovation involves the emergence of precision medicine and targeted therapies tailored to individual patients based on specific molecular characteristics of their tumors. Immunotherapies, such as checkpoint inhibitors, have shown promise in some cases by enhancing the body's immune response against cancer cells. Additionally, advancements in minimally invasive surgical techniques, including robotic-assisted surgery, have improved treatment outcomes, reducing patient discomfort and recovery times.

Diagnostic tools too have evolved, with the development of liquid biopsies for early detection and monitoring of gastric cancer. These tests offer a less invasive method to analyze circulating tumor DNA, potentially allowing for quicker intervention and personalized treatment strategies. For instance, in January 2023, Eisai Co., Ltd. announced the showcasing of their research covering diverse gastrointestinal cancer types at the 2023 American Society of Clinical Oncology (ASCO) symposium on gastrointestinal cancers (#GI23), held in San Francisco, California.

Growing Regulatory Landscape

The Global Gastric Cancer Market product approvals are increasing due to the complex nature of these diseases. The increase in product approvals, collaboration, and innovation are pivotal. Research institutions, pharmaceutical companies, and regulatory bodies are collaborating closely to streamline clinical trials and expedite the approval process. Furthermore, investing in technological advancements like precision medicine and immunotherapy significantly enhances treatment outcomes, leading to more successful drug approvals.

For instance, in March 2023, Akeso, Inc., finalized the enrolment of patients for its crucial Phase III clinical trial for cadonilimab (AK104), a groundbreaking PD-1/CTLA-4 bi-specific antibody. The achievement represents a significant milestone as it is the first dual-immune checkpoint bi-specific antibody drug to receive approval and enter the market. The advancement brings cadonilimab one step closer to its official launch for a major indication following the successful approval for the treatment of cervical cancer.

Strategic Partnership Between Key Players

A strategic partnership between key players in global gastric cancer market holds significant promise for advancing the diagnosis, treatment, and overall management of the prevalent malignancy. Such collaborations can leverage the combined expertise and resources of pharmaceutical companies, research institutions, and healthcare providers to address the multifaceted challenges gastric cancer poses. These partnerships can accelerate the development of innovative therapies, diagnostic tools, and treatment protocols, ultimately improving patient outcomes. By pooling their knowledge and capabilities, stakeholders can better understand gastric cancer molecular underpinnings and optimize clinical trial designs, potentially leading to more effective and targeted treatments. Additionally, partnerships can facilitate early detection and screening programs, thereby increasing the chances of early intervention, and reducing the global burden of gastric cancer.

For instance, during February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb entered a contract with Prime Research Institute for Medical RWD, Inc. This agreement aimed to conduct extensive, industry-sponsored, multi-institutional clinical research involving patients with gastric cancer. The study focused on the treatment involving Opdivo in conjunction with chemotherapy.

Development of Precision Medicine

Precision medicine in the global gastric cancer market has significantly advanced, leveraging individual patient variability in genes, environment, and lifestyle for tailored treatment. Innovations like next-generation sequencing, biomarker identification, and molecular profiling have revolutionized diagnosis and therapy selection. Targeted therapies, like trastuzumab for HER2-positive tumors, exemplify precision medicine's impact by improving patient outcomes. Companion diagnostics enables patients to respond to specific treatments, optimizing efficacy, and reducing adverse effects. The integration of big data analytics and artificial intelligence further refines treatment strategies, predicting responses and disease progression.

However, challenges such as cost, accessibility, and data interpretation persist, hindering widespread implementation. For instance, according to an article published in July 2022 in PubMed, the progress of precision medicine has continuously received substantial support from the remarkable strides achieved in both local and global studies concerning molecular targeted therapy for gastric cancer in recent years.

Impact of COVID-19

The global healthcare systems were widely impacted by the COVID-19 pandemic, significantly influencing the market for gastric cancer therapy. The diagnosis and treatment of gastric cancer experienced delays or cancellations owing to the worldwide lockdown measures. For example, a March 2023 article in PubMed highlighted how during the initial period of the pandemic, the care of gastric cancer patients worldwide suffered due to reduced multidisciplinary team meetings and a decline in elective gastrectomy. Amid the COVID-19 pandemic, delays in diagnosing and treating cancer placed patients at risk of negative consequences. These delays significantly affected the market's growth due to treatment and diagnosis disruptions. Nevertheless, the market for gastric cancer treatments has now reverted to its pre-pandemic state.

Report Scope

“Gastric Cancer Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global gastric cancer market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, COVID-19 impact, opportunities, and forecast between 2024 -2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2023
Historical Period	2017-2022
Forecast Period	2024-2031F
Projected Growth Rate	CAGR of 12.88% between 2024 and 2031F
Revenue Forecast in 2031	USD 12.83 billion
Units	Revenue in USD billion
Segments Covered	Type, Stages, Drug Class, Diagnosis, Treatment, Route of Administration, Distribution Channel, End-users
Regions Covered	North America, Europe, Asia-Pacific, Middle East and Africa, South America
Key Companies Profiled	Novartis AG, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Sanofi, Bayer AG, Johnson & Johnson Private Limited, Cipla Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Hikma Pharmaceuticals PLC
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfil your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In this report, Global Gastric Cancer Market has been segmented into the following categories: 

·         By Type

o   Adenocarcinoma

o   Lymphoma

o   Gastrointestinal Stromal Tumor

o   Carcinoid Tumor

o   Others

·         By Stages

o   Stage I

o   Stage II

o   Stage III

o   Stage IV

o   Others

·         By Drug Class

o   PD-1/PD-L1 Inhibitors

o   HER2 Antagonists

o   VEGFR2 Antagonists

o   Others

·         By Diagnosis

o   Endoscopy

o   Biopsy

o   Imaging Tests

o   Exploratory Surgery

o   Other

·         By Treatment

o   Surgery

o   Radiation Therapy

o   Chemotherapy

o   Targeted Therapy

o   Palliative Care

o   Others

·         By Route of Administration

o   Oral

o   Parenteral

o   Others

·         By Distribution Channel

o   Hospital Pharmacy

o   Online Pharmacy

o   Retail Pharmacy

·         By End-users

o   Hospitals

o   Homecare

o   Speciality Centres

o   Others

·         By Region

o   North America

o   Europe

o   Asia Pacific

o   South America

o   Middle East & Africa

Key Players Landscape and Outlook

The competitive landscape of global gastric cancer market offers comprehensive insights on competitors. These details include company profiles, financial standings, revenue generation, market opportunities, research and development investments, new market strategies, international reach, manufacturing facilities, production capabilities, strengths and weaknesses, product launches, product diversity, and dominant applications. It is important to note that the mentioned data points specifically pertain to the companies' involvement in the global gastric cancer market.

BDR Pharma announced the introduction of Furmecil (recognized as S-1), a composite of three medications—Tegafur, Gimeracil, and Oteracil, in April 2022. Oral medication is specified for treating advanced gastric cancer in adults. According to a statement from BDR Pharma, Furmecil has displayed notable efficacy and a positive safety profile in its use.

Key Players Operating in Global Gastric Cancer Market are:

·         Novartis AG

·         F. Hoffmann-La Roche Ltd.

·         Bristol Myers Squibb Company

·         Eli Lilly and Company

·         Teva Pharmaceutical Industries Ltd.

·         Pfizer, Inc.

·         Mylan N.V.

·         Merck & Co., Inc.

·         Sanofi, Bayer AG

·         Johnson & Johnson Private Limited

·         Cipla Inc.

·         AbbVie Inc.

·         Sun Pharmaceutical Industries Ltd.

·         Aurobindo Pharma

·         Hikma Pharmaceuticals PLC

Markets and Data’s reports answer the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments and each segment's market size and growth?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global gastric cancer market, you may approach our team at info@marketsandata.com